Davis Investment Partners LLC Buys Shares of 3,240 IQVIA Holdings Inc. $IQV

Davis Investment Partners LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 3,240 shares of the medical research company’s stock, valued at approximately $553,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Fifth Third Wealth Advisors LLC grew its holdings in IQVIA by 11.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,588 shares of the medical research company’s stock valued at $271,000 after purchasing an additional 162 shares during the period. OP Asset Management Ltd bought a new stake in IQVIA in the first quarter valued at approximately $5,155,000. Banque Cantonale Vaudoise raised its holdings in IQVIA by 41.5% in the first quarter. Banque Cantonale Vaudoise now owns 8,525 shares of the medical research company’s stock worth $1,454,000 after purchasing an additional 2,502 shares during the period. Apella Capital LLC boosted its position in shares of IQVIA by 5.1% during the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of IQVIA by 3.3% during the first quarter. Assenagon Asset Management S.A. now owns 231,192 shares of the medical research company’s stock worth $39,427,000 after purchasing an additional 7,467 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IQV. HSBC set a $210.00 price objective on shares of IQVIA in a research report on Wednesday, June 3rd. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Evercore reaffirmed an “outperform” rating and set a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. Finally, Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $222.56.

IQVIA Price Performance

Shares of NYSE IQV opened at $185.76 on Thursday. The company has a fifty day moving average price of $173.95 and a 200 day moving average price of $190.34. The firm has a market cap of $31.00 billion, a PE ratio of 23.02, a PEG ratio of 1.47 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.